Austin, July 18, 2025 (GLOBE NEWSWIRE) -- Lymphoma Treatment Market Size & Growth Analysis:
According to SNS Insider, the global Lymphoma Treatment Market was valued at USD 7.01 billion in 2023 and is projected to reach USD 14.66 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.54% during the forecast period of 2024-2032.
The global lymphoma treatment market is growing with increasing prevalence of Hodgkin as well as non-Hodgkin lymphoma, a growing trend of immunotherapy, and a large amount of research and development in lymphoma due to increased research and development activities, including increasing use of immunotherapies such as antibodies and drugs, cells, and CAR-T. The rise in demand has also been driven by technological advances in diagnostics, greater patient and physician awareness, and rising obesity in many countries.
Request Your Free Sample Copy of the Lymphoma Treatment Market Report Today: https://www.snsinsider.com/sample-request/3427
The U.S. lymphoma treatment market was estimated at USD 2.71 billion in 2023, and it is expected to reach USD 5.50 billion by 2032, at a CAGR of 8.20% during the forecast period of 2024-2032. In North America, the U.S. dominated the lymphoma treatment market on account of a robust healthcare infrastructure and the existence of leading drug manufacturers, and since the uptake of next-generation drugs like the CAR-T cell therapies is significant.
Major Players Analysis Listed in this Report are:
- AstraZeneca (Calquence, Lumoxiti)
- Bayer AG (Aliqopa, Vitrakvi)
- Takeda Pharmaceutical Company Limited (Adcetris, Ninlaro)
- Kite Pharma, Inc. / Gilead Sciences, Inc. (Yescarta, Tecartus)
- Novartis AG (Kymriah, Tafinlar)
- Teva Pharmaceutical Industries Ltd. (Treanda, Trisenox)
- Spectrum Pharmaceuticals, Inc. (Beleodaq, Folotyn)
- Janssen Pharmaceuticals, Inc. (Imbruvica, Darzalex)
- Bristol Myers Squibb Company (Opdivo, Breyanzi)
- Genentech, Inc. (Rituxan, Gazyva)
- F. Hoffmann-La Roche Ltd (MabThera, Polivy)
- Eli Lilly and Company (Verzenio, Cyramza)
- Merck & Co., Inc. (Keytruda, Zolinza)
- AbbVie Inc. (Venclexta, Empliciti)
- Amgen Inc. (Blincyto, Kyprolis)
- Sanofi (Sarclisa, Libtayo)
- BeiGene Ltd. (Brukinsa, Tevimbra)
- Incyte Corporation (Monjuvi, Pemazyre)
- Seagen Inc. (Tivdak, Adcetris)
- Regeneron Pharmaceuticals, Inc. (Libtayo, Odronextam
Lymphoma Treatment Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 7.01 billion |
| Market Size by 2032 | US$ 14.66 billion |
| CAGR (2024–2032) | 8.54% |
| U.S. Market 2023 | USD 2.71 billion |
| U.S. Forecast by 2032 | USD 5.50 billion |
| Base Year | 2023 |
| Forecast Period | 2024–2032 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
Market Segment Insights
Based on Type, Non-Hodgkin Lymphoma is the Largest Segment in the Lymphoma Treatment Market
In 2023, the non-Hodgkin lymphoma segment dominated the lymphoma treatment market with an 85.54% market share due to its more common occurrence than HL. NHL consists of several subtypes, which often cannot be managed simply and require complex and long-term therapeutic strategies, including chemotherapy, immunotherapy, and advanced targeted therapies.
MabThera/Rituxan is the Leading Segment in Lymphoma Treatment by Drug
In 2023, the Rituxan/MabThera dominated the lymphoma treatment market with a 22% market share due to being one of the first-line treatments for many non-Hodgkin lymphoma indications. As a CD20-targeting monoclonal antibody, Rituxan/MabThera is very effective, especially in combination with chemotherapy. Its extensive clinical adoption, survival benefits, and establishment into the standard treatment protocols further entrenched its penultimate Position.
By Distribution Channel, Hospital Pharmacies Segment Dominates the Lymphoma Treatment Market
Hospitals accounted for the largest share of the lymphoma treatment market in 2023, with a 37% market share. Hospitals are the primary facilities where patients receive advanced, specialized, or tertiary care treatments, and this is especially true of complex oncology therapies. Immunotherapies, chemotherapy, and CAR-T cell therapies are treatments that need to be handled with care, closely monitored, and inpatient care medication use is supported by hospital pharmacies.
For a Personalized Briefing with Our Industry Analysts, Connect Now: https://www.snsinsider.com/request-analyst/3427
Lymphoma Treatment Market Segmentation
By Type
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
By Drug
- Rituxan/MabThera
- Revlimid
- Imbruvica
- Adcetris
- Keytruda
- Opdivo
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Specialty Pharmacy
- Others
North America Dominates the Lymphoma Treatment Market, While Asia-Pacific Registers the Fastest Growth
North America dominated the lymphoma treatment market in 2023 with a 52% market share as it has a well-developed healthcare infrastructure, advanced treatments such as CAR-T cell therapy and monoclonal antibodies, to manufacture overall presence of the leading pharmaceutical giants. High awareness and favorable reimbursement policies, and ongoing clinical development further contribute to regional dominance. To wit, the current regulatory backing from organizations such as the FDA is accelerating the drug approval process, providing quicker access to new therapies, and further strengthening North America as the epicenter for lymphoma care.
The APAC region is projected to register the highest CAGR in the lymphoma treatment market during the forecast period due to the rising healthcare infrastructure, prevalence of lymphoma, and better access to cancer care. In China and India, for instance, governments are investing in health care infrastructure upgradation and local biotech innovation. Furthermore, growing disease awareness, higher diagnosis rates, and the cost-effectiveness of biosimilars are factors that are driving the treatment adoption.
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Lymphoma Treatment Market by Type
8. Lymphoma Treatment Market by Drug
9. Lymphoma Treatment Market by Distribution Channel
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion
Buy the Full Lymphoma Treatment Market Report (Single-User License) Now: https://www.snsinsider.com/checkout/3427
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
